Literature DB >> 22886849

A preliminary disease severity score for juvenile systemic sclerosis.

Francesco La Torre1, Giorgia Martini, Ricardo Russo, Maria Marta Katsicas, Fabrizia Corona, Giuseppina Calcagno, Fernanda Falcini, Fabio Vittadello, Francesco Zulian.   

Abstract

OBJECTIVE: To develop a preliminary disease severity score for juvenile systemic sclerosis (SSc).
METHODS: We conducted an evidence- and consensus-based study that included the following 5 phases: 1) prospective collection of data regarding the demographic and clinical characteristics of patients with diffuse juvenile SSc who were followed up for at least 4 years or until death; 2) blinded evaluation of the disease course profiles of these patients by experts in juvenile SSc, so that patient profiles with a defined clinical course could be used as the gold standard for the score validation phase; 3) definition of candidate severity indices to be included in potential scores; 4) selection of the pediatric severity score with the best statistical performance, as determined by its ability to classify individual patients as having improvement or worsening of disease compared with baseline values or the previous evaluation; 5) validation of the efficiency of the selected score in patients with a mild, moderate, or severe disease course and comparison with the Medsger severity score for adults with SSc.
RESULTS: Thirty-five patients classified as having a mild (n = 17), moderate (n = 10), or severe (n = 8) disease course entered the study. The selected pediatric SSc score, defined as the Juvenile Systemic Sclerosis Severity Score (J4S), included indices of 9 organ systems each scored on a scale of 0-4. To weight the importance of the involvement of different organ systems, a coefficient of severity was introduced. Compared with the modified Medsger severity score, the J4S performed significantly better in detecting change in severity, both in patients with a moderate disease course (0.89 versus 0.52) and in patients with a severe disease course (0.82 versus 0.75).
CONCLUSION: The J4S is a valid instrument to assess disease severity in juvenile SSc.
Copyright © 2012 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22886849     DOI: 10.1002/art.34652

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  13 in total

1.  Clinical and laboratory profile of juvenile-onset systemic sclerosis in a Brazilian cohort.

Authors:  Percival D Sampaio-Barros; Adriana B Bortoluzzo; Ana Paula T Del Rio; Ana Paula Luppino-Assad; Danieli Co Andrade; João Francisco Marques-Neto
Journal:  J Scleroderma Relat Disord       Date:  2018-04-24

Review 2.  Update on juvenile systemic sclerosis.

Authors:  Ivan Foeldvari
Journal:  Curr Rheumatol Rep       Date:  2015-03       Impact factor: 4.592

Review 3.  Glucocorticoid-associated osteoporosis in chronic inflammatory diseases: epidemiology, mechanisms, diagnosis, and treatment.

Authors:  Emily von Scheven; Kathleen Jo Corbin; Stefano Stagi; Stagi Stefano; Rolando Cimaz
Journal:  Curr Osteoporos Rep       Date:  2014-09       Impact factor: 5.096

4.  Clinical Characteristics and Factors Associated With Disability and Impaired Quality of Life in Children With Juvenile Systemic Sclerosis: Results From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry.

Authors:  Brandi E Stevens; Kathryn S Torok; Suzanne C Li; Nicole Hershey; Megan Curran; Gloria C Higgins; Katharine F Moore; C Egla Rabinovich; Samuel Dodson; Anne M Stevens
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-11-08       Impact factor: 4.794

Review 5.  Current Research in Outcome Measures for Pediatric Rheumatic and Autoinflammatory Diseases.

Authors:  Erkan Demirkaya; Alessandro Consolaro; Hafize Emine Sonmez; Gabriella Giancane; Dogan Simsek; Angelo Ravelli
Journal:  Curr Rheumatol Rep       Date:  2016-02       Impact factor: 4.592

6.  Evaluation of six-minute walk test in juvenile systemic sclerosis.

Authors:  Oya Koker; Amra Adrovic; Sezgin Sahin; Mehmet Yildiz; Kenan Barut; Rukiye Eker Omeroglu; Ozgur Kasapcopur
Journal:  Rheumatol Int       Date:  2018-10-26       Impact factor: 2.631

7.  An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups.

Authors:  Murray Baron; Bashar Kahaleh; Elana J Bernstein; Lorinda Chung; Philip J Clements; Christopher Denton; Robyn T Domsic; Nava Ferdowsi; Ivan Foeldvari; Tracy Frech; Jessica K Gordon; Marie Hudson; Sindhu R Johnson; Dinesh Khanna; Zsuzsannah McMahan; Peter A Merkel; Sonali Narain; Mandana Nikpour; John D Pauling; Laura Ross; Antonia Maria Valenzuela Vergara; Alessandra Vacca
Journal:  J Scleroderma Relat Disord       Date:  2018-07-18

8.  Juvenile Scleroderma: A Referral Center Experience.

Authors:  Amra Adrovic; Sezgin Şahin; Kenan Barut; Özgür Kasapçopur
Journal:  Arch Rheumatol       Date:  2018-01-18       Impact factor: 1.472

9.  Early detection of ventricular dysfunction in juvenile systemic sclerosis by speckle tracking echocardiography.

Authors:  Giovanni Civieri; Biagio Castaldi; Giorgia Martini; Alessandra Meneghel; Ornella Milanesi; Francesco Zulian
Journal:  Rheumatology (Oxford)       Date:  2021-01-05       Impact factor: 7.580

10.  Biological and Clinical Changes in a Pediatric Series Treated with Off-Label JAK Inhibitors.

Authors:  Alessia Pin; Alessandra Tesser; Serena Pastore; Valentina Moressa; Erica Valencic; Anna Arbo; Alessandra Maestro; Alberto Tommasini; Andrea Taddio
Journal:  Int J Mol Sci       Date:  2020-10-20       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.